Physician

Caroline Marie Behler, M.D., M.S.

According to 2025 Medicare claims, Caroline Behler, M.D., M.S. (NPI: 1518155357) practices hematology/oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Francisco, CA. This provider's primary affiliated billing organization is PACIFIC HEMATOLOGY ONCOLOGY ASSOC (NPI: 1073630406; TIN: 942547219) and primary practice location at 94115-2376. Behler is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Behler's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 586 traditional Medicare patients, billed 103,008 HCPCS/CPT codes, and received $1,927,883 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,659 prescription claims across 207 beneficiaries totaling $8,298,907 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 15 claims. Open Payments data shows 60 records totaling $2,341. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $843,680 to $1,927,883. Similarly, Part D prescription costs have risen steadily, from $1,091,625 to $8,298,907. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $428 and ending at $1,705.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	256	61,876	$843,680
2016	409	106,080	$1,341,620
2017	416	118,543	$1,511,923
2018	390	135,529	$1,617,210
2019	416	117,170	$1,449,138
2020	394	87,946	$1,800,356
2021	423	89,394	$1,993,013
2022	517	92,803	$1,669,236
2023	567	124,328	$1,957,973
2024	586	103,008	$1,927,883

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	112	823	$1,091,625
2016	136	1,003	$2,040,347
2017	162	1,386	$3,144,368
2018	176	1,437	$4,127,246
2019	192	1,802	$6,418,136
2020	202	2,044	$8,292,254
2021	205	2,184	$8,573,795
2022	243	2,491	$12,344,863
2023	215	2,167	$11,568,219
2024	207	1,659	$8,298,907

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	32	$23,390
2016	N/R	69	$12,174
2017	N/R	172	$19,079
2018	N/R	222	$15,603
2019	11	194	$9,553
2020	N/R	106	$4,997
2021	N/R	106	$37,481
2022	N/R	47	$1,864
2023	N/R	15	$2,905
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	117	197	$166
96413	Administration of chemotherapy into vein, 1 hour or less	76	268	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	406	917	$113
96372	Injection of drug or substance under skin or into muscle	82	267	$14
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	194	711	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	79	2,198	$1,142,710
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	62	959	$586,601
Tagrisso	Osimertinib Mesylate	32	960	$519,602
Pomalyst	Pomalidomide	27	812	$482,368
Jakafi	Ruxolitinib Phosphate	33	1,170	$451,305

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$2,341	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Caroline Marie Behler, M.D., M.S.?

Tedicare shows public-source Medicare data for Caroline Marie Behler, M.D., M.S. (NPI 1518155357), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Caroline Marie Behler, M.D., M.S. have ACO affiliation data?

Caroline Marie Behler, M.D., M.S. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Caroline Marie Behler, M.D., M.S.?

Caroline Marie Behler, M.D., M.S. is linked to PACIFIC HEMATOLOGY ONCOLOGY ASSOC (billing NPI 1073630406) in the available physician profile data.

Does Caroline Marie Behler, M.D., M.S. have Open Payments data?

Caroline Marie Behler, M.D., M.S. has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.